On the stock market since 2015, it operates in the world of health and science. It has 5,600 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
The price looks reasonable next to what the company earns.
This grade is a blend: the profit side is strong, the sales tempo slow.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
An investor who bought at the very peak is down 96% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The average analyst price target is $8.25 — 27% above today’s price.
A loss of $200.3M against $2.5B in annual sales. And on top of that, sales fell from the year before.
This stock swings about 2.1 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, TDOC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: TDOC has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.